These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission. Briand N; Le Coeur S; Traisathit P; Karnchanamayul V; Hansudewechakul R; Ngampiyasakul C; Bhakeecheep S; Ithisukanan J; Hongsiriwon S; McIntosh K; Lallemant M Pediatr Infect Dis J; 2006 Apr; 25(4):325-32. PubMed ID: 16567984 [TBL] [Abstract][Full Text] [Related]
5. Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy. The Italian register for HIV Infection in Children. AIDS; 1999 May; 13(8):927-33. PubMed ID: 10371173 [TBL] [Abstract][Full Text] [Related]
6. Risk of cancer in children exposed to didanosine in utero. Hleyhel M; Goujon S; Delteil C; Vasiljevic A; Luzi S; Stephan JL; Reliquet V; Jannier S; Tubiana R; Dollfus C; Faye A; Mandelbrot L; Clavel J; Warszawski J; Blanche S; AIDS; 2016 May; 30(8):1245-56. PubMed ID: 26854809 [TBL] [Abstract][Full Text] [Related]
7. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Noguera A; Fortuny C; Muñoz-Almagro C; Sanchez E; Vilaseca MA; Artuch R; Pou J; Jimenez R Pediatrics; 2004 Nov; 114(5):e598-603. PubMed ID: 15492359 [TBL] [Abstract][Full Text] [Related]
8. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. Culnane M; Fowler M; Lee SS; McSherry G; Brady M; O'Donnell K; Mofenson L; Gortmaker SL; Shapiro DE; Scott G; Jimenez E; Moore EC; Diaz C; Flynn PM; Cunningham B; Oleske J JAMA; 1999 Jan; 281(2):151-7. PubMed ID: 9917118 [TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS. AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371 [TBL] [Abstract][Full Text] [Related]
10. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. Senise JF; Castelo A; Martínez M AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356 [TBL] [Abstract][Full Text] [Related]
11. Antenatal and neonatal antiretroviral therapy in HIV-infected women and their infants: a review of safety issues. Thorne C; Newell ML Med Wieku Rozwoj; 2003; 7(4 Pt 1):425-36. PubMed ID: 15010553 [TBL] [Abstract][Full Text] [Related]
12. Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. Aldrovandi GM; Chu C; Shearer WT; Li D; Walter J; Thompson B; McIntosh K; Foca M; Meyer WA; Ha BF; Rich KC; Moye J Pediatrics; 2009 Dec; 124(6):e1189-97. PubMed ID: 19933732 [TBL] [Abstract][Full Text] [Related]
13. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV. Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883 [TBL] [Abstract][Full Text] [Related]
14. Risk of cancer in children exposed to antiretroviral nucleoside analogues in utero: The french experience. Hleyhel M; Goujon S; Sibiude J; Tubiana R; Dollfus C; Faye A; Mandelbrot L; Clavel J; Warszawski J; Blanche S; Environ Mol Mutagen; 2019 Jun; 60(5):404-409. PubMed ID: 29206312 [TBL] [Abstract][Full Text] [Related]
15. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Lindegren ML; Rhodes P; Gordon L; Fleming P; ; Ann N Y Acad Sci; 2000 Nov; 918():222-35. PubMed ID: 11131709 [TBL] [Abstract][Full Text] [Related]
16. Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors. Walker VE; Poirier MC Environ Mol Mutagen; 2007; 48(3-4):159-65. PubMed ID: 17358025 [No Abstract] [Full Text] [Related]
17. HIV and mitochondrial toxicity in children. Foster C; Lyall H J Antimicrob Chemother; 2008 Jan; 61(1):8-12. PubMed ID: 17999978 [TBL] [Abstract][Full Text] [Related]
18. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. Floridia M; Mastroiacovo P; Tamburrini E; Tibaldi C; Todros T; Crepaldi A; Sansone M; Fiscon M; Liuzzi G; Guerra B; Vimercati A; Vichi F; Vicini I; Pinnetti C; Marconi AM; Ravizza M; BJOG; 2013 Nov; 120(12):1466-75. PubMed ID: 23721372 [TBL] [Abstract][Full Text] [Related]
19. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Viganò A; Mora S; Giacomet V; Stucchi S; Manfredini V; Gabiano C; Salvini F; Cellini M; Tamburrini E; Puzzovio M; Zuccotti GV Antivir Ther; 2011; 16(8):1259-66. PubMed ID: 22155907 [TBL] [Abstract][Full Text] [Related]
20. No relation between in-utero exposure to HAART and intrauterine growth retardation. Briand N; Mandelbrot L; Le Chenadec J; Tubiana R; Teglas JP; Faye A; Dollfus C; Rouzioux C; Blanche S; Warszawski J; AIDS; 2009 Jun; 23(10):1235-43. PubMed ID: 19424054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]